TRAF2 and invasive breast carcinoma: Our investigation further identified that TRAF2 demonstrated increased expression in a variety of cancer types, including BLCA, breast invasive carcinoma (BRCA), CHOL, COAD, esophageal carcinoma (ESCA), HNSC, KICH, KIRC, KIRP, LIHC, LUAD, LUSC, prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), STAD, and UCEC.